经尿道膀胱肿瘤电切联合表柔比星膀胱灌注治疗非肌层浸润性膀胱癌的临床效果

Clinical effects of transurethral resection combined with intravesical instillation of epirubicin on non-muscle invasive bladder cancer

目的探讨经尿道膀胱肿瘤电切术联合表柔比星膀胱灌注治疗非肌层浸润性膀胱癌的临床效果。方法选取非肌层浸润性膀胱癌患者82例,并将其随机分为两组,每组41例。两组非肌层浸润性膀胱癌患者均接受经尿道膀胱肿瘤电切手术治疗,研究组术后给予表柔比星膀胱灌注治疗,对照组术后实施卡介苗膀胱灌注治疗。记录两组非肌层浸润性膀胱癌患者随访情况(复发率)、不良反应(药物相关)发生率。结果经随访,研究组疾病复发率(7.32%)少于对照组(31.15%),差异有统计学意义(P<0.05);观察组非肌层浸润性膀胱癌患者药物相关不良反应发生率(41.46%)与对照组(36.59%)比较,差异未见统计学意义(P>0.05)。结论在经尿道膀胱肿瘤电切术治疗非肌层浸润性膀胱癌基础上,加用表柔比星膀胱灌注治疗可显著降低患者疾病复发率,对保障其预后具有重要意义。

Objective To investigate the clinical effect of transurethral resection of bladder tumor combined with intravesical instillation of epirubicin non-muscle invasive bladder cancer.Methods Eighty-two patients with non-muscle invasive bladder cancer were selected and randomly divided into two groups,with 41 cases in each group. All patients in both groups were treated with transurethral resection of bladder tumor surgery,and the patients in observation group received postoperative intravesical instillation of epirubicin therapy,while patients of the control group received the postoperative intravesical instillation of BCG treatment. The follow-up of two groups of patients with non-muscle invasive bladder cancer（ recurrence rate） and the adverse drug reactions（ drug related） were recorded.Results The recurrence rate of the patients in observation group（ 7. 32%） were lower than that of the control group（ 31. 15%）,the difference was significant（ P 0. 05）; there was no significant difference in the related adverse reaction rate between the two groups（ P 0. 05）. Conclusions Transurethral resection combined with epirubicin intravesical therapy of bladder tumor in the treatment of non-muscle invasive bladder cancer foundation can significantly reduce the relapse rate of disease,and has remarkable significance to guarantee the prognosis.